Triple-negative breast cancer (TNBC) cells are identified by the lack of receptor targeted therapies including human epidermal receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR), and are major cause of lack of better therapies, consisting about 15–20% of recently diagnosed breast cancer [1]. This evidence concerns the gene ESR1 and breast carcinoma.